What is Acorai?
Acorai is a pioneering MedTech enterprise dedicated to transforming the standard of care for patients suffering from heart failure. The company specializes in the development of non-invasive hemodynamic monitoring solutions that provide clinicians with actionable, real-time data regarding intracardiac pressures. Its core innovation, the SAVE Sensor System, leverages a sophisticated combination of seismic, acoustic, visual, and electric sensors to detect hemodynamic congestion with high precision.
By moving away from invasive diagnostic procedures, Acorai aims to personalize heart failure therapy and improve patient outcomes on a global scale. With clinical validation across a cohort of over 2,000 patients, the company has established a strong foundation for its technology, positioning itself as a critical player in the digital health and diagnostic monitoring sectors. Their collaborative approach with healthcare providers ensures that their technological advancements are directly aligned with the practical requirements of modern clinical environments.
How much funding has Acorai raised?
Acorai has raised a total of $17.6M across 3 funding rounds:
Grant
$10.7M
Grant
$2.4M
Angel/Seed
$4.5M
Grant (2023): $10.7M with participation from The European Innovation Council
Grant (2023): $2.4M led by The European Innovation Council
Angel/Seed (2024): $4.5M supported by CARMA FUND Management
Key Investors in Acorai
The European Innovation Council
A prominent European entity focused on fostering innovation within the academic and research sectors to bridge the gap between laboratory discovery and market application.
CARMA FUND Management
An early-stage investment firm based in Germany that specializes in supporting high-potential Life Science and Healthcare technologies through flexible capital deployment.
What's next for Acorai?
With the recent infusion of capital, Acorai is poised to enter a pivotal phase of commercialization and regulatory advancement. The strategic focus will likely center on expanding clinical trials, securing necessary regulatory clearances for the SAVE Sensor System, and deepening partnerships with major healthcare institutions to facilitate widespread adoption. As the company scales, it will continue to refine its diagnostic algorithms, ensuring that its non-invasive monitoring tools remain at the forefront of cardiac care innovation.
Looking ahead, the firm is well-positioned to disrupt traditional diagnostic workflows, potentially reducing the burden on healthcare systems by enabling earlier intervention and more precise management of chronic heart conditions. The combination of institutional support and a proven technological platform provides Acorai with the necessary resources to navigate the complexities of the MedTech market and achieve long-term growth in the cardiovascular space.
